TABLE 2

Markers of infectious status and overall health

Control subjectsCF patients
TNF (pg/ml)3.0 (0–7.2)0.9 (0–15.3)
Interleukin-6 (pg/ml)1.3 (0–7.7)3.2 (0.9–14.5)
α-Interferon (pg/ml)0.02 ± 0.022.63 ± 0.81*
C-reactive protein (mg/dl)0.3 (0–0.9)0.2 (0–1.8)
Epinephrine (pg/ml)61 (25–260)64 (42–358)
Norepinephrine (pg/ml)173 (99–536)232 (80–411)
Cortisol (μg/dl)15 ± 118 ± 1
Glucagon (pg/ml)56 ± 754 ± 13
Growth hormone (μg/l)4 ± 13 ± 1
Fasting insulin (μU/ml)5 ± 24 ± 1
Fasting glucose (mg/dl)90 ± 8101 ± 6
IGF-I (ng/ml)205 ± 13206 ± 14
IGFBP3 (mg/l)2.28 ± 0.242.52 ± 0.15
REE1271 ± 561546 ± 65*
REE/kg FFM31 ± 133 ± 1
Vo2184 ± 8220 ± 9*
Vco2161 ± 7196 ± 8*
RQ0.87 ± 0.010.90 ± 0.01
SF-36 score89 ± 169 ± 5
NIH scoreNA76 ± 1
FEV1 % predictedNA68 ± 7
  • Data that were not normally distributed are medians (range); otherwise, data are means ± SE.

  • * P < 0.01.

  • P < 0.001 CF patients vs. control subjects.